Plexera to Present at Major Antibody Conference
Lumera zu myNews hinzufügen Was ist das?
Plexera Biosciences LLC, a wholly owned subsidiary of Lumera Corporation
(NASDAQ:LMRA), announced today it will be presenting at IBC’s
18th Annual International Antibody Engineering
Conference. The conference is being held in San Diego and begins on
Sunday, December 2, 2007 and continues through Thursday, December 6,
2007.
Ronald P. Dudek, Plexera’s Director of
Business Development, will be giving a technology workshop on Tuesday,
December 4 entitled "Surface Plasmon Resonance
Analysis of High-Density Microarrays; Innovations in Antibody Discovery
Technology.” The workshop will illustrate the
use of Plexera’s ProteomicProcessor™instrument
and NanoCapture™ microarray slides for
increasing the efficiency of the antibody discovery process, and discuss
Plexera’s ExpressTag™
technology for streamlining the antibody phage display discovery
process. The ProteomicProcessor™ is scheduled
for commercial launch at the PEGS meeting in Boston, April 28-May 2.
Additional information on the conference can be obtained at http://www.ibclifesciences.com/antibodyeng/6679.xml.
About Plexera Biosciences LLC
Plexera Biosciences LLC., a wholly owned subsidiary of Lumera
Corporation (NASDAQ:LMRA), develops and manufactures advanced analytical
tools and methods that enable life science researchers to probe the
human proteome for improved diagnostics, therapeutics, and knowledge of
the human condition. For more information, please visit www.plexera.com.
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties. Factors
that could cause actual results to differ materially from those
projected in the company's forward-looking statements include the
following: market acceptance of our technologies and products; our
ability to obtain financing; our financial and technical resources
relative to those of our competitors; our ability to keep up with rapid
technological change; government regulation of our technologies; our
ability to enforce our intellectual property rights and protect our
proprietary technologies; the ability to obtain additional contract
awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical
milestones in key products; and other risk factors identified from time
to time in the company's SEC reports, including its Annual Report on
Form 10-K, and its Quarterly Reports on Form 10-Q.
